KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $3.0 million.

  • Halozyme Therapeutics' Capital Expenditures rose 9973.63% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 1606.45%. This contributed to the annual value of $10.7 million for FY2024, which is 3006.41% down from last year.
  • Halozyme Therapeutics' Capital Expenditures amounted to $3.0 million in Q3 2025, which was up 9973.63% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Capital Expenditures ranged from a high of $11.4 million in Q1 2023 and a low of -$1.6 million during Q2 2023
  • Over the past 5 years, Halozyme Therapeutics' median Capital Expenditures value was $1.5 million (recorded in 2024), while the average stood at $2.1 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 228164.56% in 2022, then plummeted by 26766.53% in 2023.
  • Halozyme Therapeutics' Capital Expenditures (Quarter) stood at $158000.0 in 2021, then skyrocketed by 2281.65% to $3.8 million in 2022, then tumbled by 31.01% to $2.6 million in 2023, then rose by 17.57% to $3.1 million in 2024, then decreased by 0.72% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $1.6 million for Q2 2025, and $950000.0 during Q1 2025.